Help on Tele2, tariffs, questions

The page contains instructions for use Kagotsela. It is available in various dosage forms of the drug (12 mg tablets), and also has a number of analogues. This abstract has been verified by experts. Leave your feedback on the use of Kagocel, which will help other site visitors. The drug is used for various diseases (treatment and prevention of influenza, ARVI, colds). The product has a number of side effects and interactions with other substances. Doses of the drug differ for adults and children. There are restrictions on the use of the medicine during pregnancy and breastfeeding. Treatment with Kagocel can only be prescribed by a qualified doctor. The duration of therapy may vary and depends on the specific disease.

Instructions for use and dosage

For adults

For the treatment of influenza and ARVI, it is prescribed in the first 2 days - 2 tablets 3 times a day, in the next 2 days - 1 tablet 3 times a day. A total of 18 tablets per course lasting 4 days.

Prevention of influenza and ARVI is carried out in 7-day cycles: 2 days - 2 tablets 1 time per day, break for 5 days. Then the cycle is repeated. The duration of the preventive course varies from 1 week to several months.

For the treatment of herpes, 2 tablets are prescribed 3 times a day for 5 days. A total of 30 tablets for a course lasting 5 days.

Children aged 6 years and older

For the treatment of influenza and ARVI, it is prescribed in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. A total of 10 tablets per course lasting 4 days.

Prevention of influenza and ARVI is carried out in 7-day cycles: 2 days - 1 tablet once a day, a break for 5 days, then the cycle is repeated. The duration of the preventive course is from 1 week to several months.

Release forms

Tablets 12 mg. There is no specific pediatric form of the drug noted.

Kagocel- antiviral drug. Interferon synthesis inducer.

Causes the formation in the body of so-called late interferon, which is a mixture of alpha and beta interferons with high antiviral activity. Kagocel causes the production of interferon in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel is taken orally, the interferon titer in the blood serum reaches maximum values ​​after 48 hours. The body's interferon response to the administration of Kagocel is characterized by prolonged (up to 4-5 days) circulation of interferon in the bloodstream. The dynamics of interferon accumulation in the intestine when taking the drug orally does not coincide with the dynamics of circulating interferon titers. In the blood serum, the interferon content reaches high values ​​only 48 hours after taking the drug Kagocel, while in the intestine the maximum interferon production is observed after 4 hours.

The greatest effectiveness in treatment with Kagocel is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, incl. and immediately after contact with an infectious agent.

Pharmacokinetics

When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. 24 hours after oral administration, the drug accumulates mainly in the liver, and to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content in the brain is explained by the high molecular weight of the drug, which makes it difficult to penetrate the blood-brain barrier (BBB). It is excreted mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, including 90% in feces and 10% in urine. The drug was not detected in exhaled air.

Indications

• prevention and treatment of influenza and other acute respiratory viral infections in adults and children aged 6 years and older;
• treatment of herpes in adults.

Contraindications

• pregnancy;
• children under 6 years of age;
• increased individual sensitivity.

special instructions

To achieve a therapeutic effect, taking Kagocel should begin no later than the 4th day from the onset of the disease.

Kagocel combines well with other antiviral drugs, immunomodulators and antibiotics.

Side effect

• allergic reactions.

Drug interactions

With the simultaneous use of the drug Kagocel with other antiviral drugs, immunomodulators and antibiotics, an additive effect is observed (they enhance the effect of each other).

Analogues of the drug Kagocel

The drug Kagocel has no structural analogues for the active substance.

Use in children

Contraindicated in children under 6 years of age.

Use during pregnancy and breastfeeding

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Kagocel, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have embryotoxic effects.

REGISTRATION NUMBER:
P N002027/01
TRADE NAME OF THE PRODUCT:
Kagocel® (Kagocel®)
INTERNATIONAL NON-PROPENTED NAME:
No.
CHEMICAL NAME:
Sodium salt of a copolymer of (1→4)-6-0-carboxymethyl-β-D-glucose, (1→4)-β-D-glucose and (21→24)-2,3,14,15,21,24 , 29,32-octahydroxy-23-(carboxymethoxymethyl)-7, 10-dimethyl-4, 13-di(2-propyl)- 19,22,26,30,31 - pentaoxaheptacyclo dotriaconta-1,3,5(28 ),6.8(27), 9(18),10, 12(17), 13.15-decaene.
DOSAGE FORM:
Pills.
COMPOUND:
Active substance:
Kagocel® 12 mg.
Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) - to obtain a tablet weighing 100 mg.
DESCRIPTION: Tablets from white with a brownish tint to light brown, round, biconvex with brown inclusions.
PHARMACOTHERAPEUTIC GROUP:
Antiviral agent.
ATH CODE:

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS
The main mechanism of action of Kagocel® is the ability to induce the production of interferons. Kagocel® causes the formation in the human body of so-called late interferons, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel® causes the production of interferons in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel® is taken orally, the interferon titer in the blood serum reaches its maximum values ​​after 48 hours. The body's interferon response to Kagocel® administration is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine when Kagocel® is taken orally does not coincide with the dynamics of circulating interferon titers. In the blood serum, the production of interferons reaches high values ​​only 48 hours after taking Kagocel®, while in the intestine the maximum production of interferons is observed after 4 hours.
Kagocel®, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have embryotoxic effects.
The greatest effectiveness in treatment with Kagocel® is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the infectious agent.

PHARMACOKINETICS
24 hours after administration to the body, Kagocel® accumulates mainly in the liver, and to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel® in the brain is explained by the high molecular weight of the drug, which makes it difficult to penetrate the blood-brain barrier. In the blood plasma the drug is found predominantly in bound form.
With daily repeated administration of Kagocel®, the volume of distribution varies widely in all organs studied. The accumulation of the drug is especially pronounced in the spleen and lymph nodes. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.
Excretion: the drug is excreted from the body mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% through the kidneys. The drug was not detected in exhaled air.

INDICATIONS FOR USE
Kagocel® is used in adults and children over the age of 3 years as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

CONTRAINDICATIONS
- Pregnancy and lactation;
- Age up to 3 years;
- Hypersensitivity to the components of the drug;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

METHOD OF APPLICATION AND DOSES

Inside, regardless of food intake.

For the treatment of influenza and ARVI, adults are prescribed 2 tablets 3 times a day in the first two days, and one tablet 3 times a day in the next two days. A total of 18 tablets per course, course duration – 4 days.
Prevention of influenza and ARVI in adults is carried out in 7-day cycles: two days - 2 tablets once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.
For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. A total of 30 tablets per course, course duration – 5 days.
For the treatment of influenza and ARVI, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet 1 time a day. A total of 6 tablets per course, course duration – 4 days.
For the treatment of influenza and ARVI, children over 6 years of age are prescribed 1 tablet 3 times a day in the first two days, and one tablet 2 times a day in the next two days. A total of 10 tablets per course, course duration – 4 days.
Prevention of influenza and ARVI in children aged 3 years and older is carried out in 7-day cycles: two days - 1 tablet once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

SIDE EFFECT
Allergic reactions may develop.
If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, Tell your doctor about this.

POSSIBILITY AND FEATURES OF USE BY PREGNANT WOMEN AND WOMEN DURING BREASTFEEDING
Due to the lack of necessary clinical data Kagocel ® It is not recommended to take during pregnancy and lactation.

INFLUENCE ON THE ABILITY TO DRIVE VEHICLES AND MECHANISMS
The effect of the drug on the ability to drive vehicles and operate machinery has not been studied.

OVERDOSE
In case of accidental overdose, it is recommended to prescribe plenty of fluids and induce vomiting.

INTERACTIONS WITH OTHER MEDICINES
Kagocel® goes well with other antiviral drugs, immunomodulators and antibiotics (additive effect).

SPECIAL INSTRUCTIONS
To achieve a therapeutic effect, take Kagocel ® should begin no later than the fourth day from the onset of the disease.

RELEASE FORM
Tablets, 12 mg.
10 tablets per blister pack made of polyvinyl chloride/polyvinylidene chloride film and aluminum foil with a heat-sealable coating.
1, 2 or 3 strip strips along with instructions for use are placed in a pack.

BEST BEFORE DATE
4 years.
After the expiration date indicated on the packaging, the drug should not be used.

Recipe (international)

Rp.: Kagocel 0.012
D.t.d.N.20 in tab.
S. In the first 2 days, 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day.

pharmachologic effect

Kagocel is a synthetic drug from the group of interferon inducers.

Kagocel is a substance of the polyphenol group, obtained by synthesis from water-soluble carmoxymethylcellulose and cotton seed polyphenol.

The drug has antimicrobial, antiviral, immunostimulating and radioprotective effects. The mechanism of action of the drug is based on its ability to stimulate the synthesis of endogenous interferon proteins, in particular, under the influence of the drug there is an increase in the amount of alpha, beta and gamma interferons. The drug helps increase the production of interferon in various cells involved in the formation of the immune response, including macrophages, granulocytes, T- and B-lymphocytes, endothelial cells and fibroblasts. Interferons are specific proteins that have pronounced antiviral activity; due to the activation of the enzymes protein kinase and adelyl synthetase, interferons inhibit the synthesis of viral proteins and viral RNA. In addition, interferons have direct and indirect antitumor activity.

After a single oral administration of the drug, the maximum production of interferon in the intestine is observed after 4 hours, and the maximum concentration of interferon in the blood plasma is achieved within 48 hours, while the high level of interferon in the blood plasma persists up to 4-5 days after the use of Kagocel. The drug in therapeutic doses has no toxic effect on the body, practically does not accumulate in organs and tissues, and does not have a teratogenic, mutagenic or embryotoxic effect.

24 hours after oral administration of the drug, its maximum concentrations are observed in the tissues of the liver, lungs, spleen and kidneys, as well as in the thymus and lymph nodes. Due to the large size of the molecule, Kagocel practically does not penetrate the blood-brain barrier and its content in the tissues of the central nervous system is insignificant.
About 20% of the administered dose of the drug is absorbed into the systemic circulation, in the plasma the drug binds to proteins and lipids, about 16% of the drug is present in the blood plasma in free form.
The drug is excreted mainly in feces, a small part of the drug is excreted in the urine (no more than 10%).

Mode of application

For adults: For oral administration.

For the treatment of influenza and ARVI, adults are prescribed 2 tablets 3 times a day in the first two days, and one tablet 3 times a day in the next two days. A total of 18 tablets per course, course duration - 4 days.

Prevention of influenza and ARVI in adults is carried out in 7-day cycles: two days - 2 tablets once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. A total of 30 tablets per course, course duration - 5 days.

For the treatment of influenza and ARVI, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet 1 time a day. A total of 6 tablets per course, course duration - 4 days.

For the treatment of influenza and ARVI, children over 6 years of age are prescribed 1 tablet 3 times a day in the first two days, and one tablet 2 times a day in the next two days. A total of 10 tablets per course, course duration - 4 days.

Prevention of influenza and ARVI in children over the age of 3 years is carried out in 7-day cycles: two days - 1 tablet once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

Indications

Kagocel is used in adults and children over the age of 3 years as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

Contraindications

Increased individual sensitivity to Kagocel.

Hereditary galactose intolerance, lactase deficiency Lapa, impaired absorption of glucose-galactose.

The drug is not used for the treatment of women during pregnancy and lactation, as well as for the treatment of children under the age of 6 years.

Side effects

The drug is usually well tolerated by patients; in isolated cases, allergic reactions may develop.

Release form

Tablets, 10 pieces in a blister, 1 blister in a cardboard package.

ATTENTION!

The information on the page you are viewing is created for informational purposes only and does not in any way promote self-medication. The resource is intended to provide healthcare workers with additional information about certain medications, thereby increasing their level of professionalism. The use of the drug "" necessarily requires consultation with a specialist, as well as his recommendations on the method of use and dosage of the medicine you have chosen.

Active substance

Kagocel

Release form, composition and packaging

◊ Pills from white with a brownish tint to light brown, round, biconvex with splashes of brown.

Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate - from 91% to 95%, (Kollidon 30) - from 3% to 4%, crospovidone (Kollidon CL) - from 3% up to 4%) - until a tablet weighing 100 mg is obtained.

10 pieces. - contour cellular packaging (1) - cardboard packs.
10 pieces. - contour cell packaging (2) - cardboard packs.
10 pieces. - contour cell packaging (3) - cardboard packs.

pharmachologic effect

The active substance is the sodium salt of a copolymer of (1→4)-6-0-carboxymethyl-β-D-glucose, (1→4)-β-D-glucose and (21→24)-2,3,14,15 ,21,24,29,32-octahydroxy-23-(carboxymethoxymethyl)-7,10-dimethyl-4,13-di(2-propyl)-19,22,26,30,31-pentaoxaheptacyclo dotriaconta-1,3 ,5(28),6,8(27),9(18),10,12(17),13,15-decaene.

Causes the formation in the human body of so-called late interferons, which are a mixture of alpha and beta interferons with high antiviral activity. Kagocel causes the production of interferons in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel is taken orally, the titer of interferons in the blood serum reaches maximum values ​​after 48 hours. The body's interferon response to the administration of Kagocel is characterized by long-term (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of accumulation of interferons in the intestine when taking the drug orally does not coincide with the dynamics of titers of circulating interferons. In the blood serum, the production of interferons reaches high values ​​only 48 hours after taking Kagocel, while in the intestine the maximum production of interferons is observed after 4 hours.

The drug Kagocel, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have embryotoxic effects.

The greatest effectiveness in treatment with Kagocel is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, incl. and immediately after contact with an infectious agent.

Pharmacokinetics

Suction and distribution

When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. 24 hours after administration to the body, the drug accumulates mainly in the liver, and to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, and blood. The low content of kagocel in the brain is explained by the high molecular weight of the drug, which hinders its penetration through the BBB. In the blood plasma, the drug is found predominantly in bound form: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.

With daily repeated administration of Kagocel, V d varies widely in all organs studied. The accumulation of the drug is especially pronounced in the spleen and lymph nodes.

Removal

It is excreted from the body mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, incl. 90% - through the intestines and 10% - through the kidneys. The drug was not detected in exhaled air.

Indications

— prevention and treatment of other acute respiratory viral infections in adults and children over 3 years of age;

- treatment of herpes in adults.

Contraindications

- pregnancy;

- lactation period (breastfeeding);

- children under 3 years of age;

- lactase deficiency, glucose-galactose malabsorption;

- hypersensitivity to the components of the drug.

Dosage

The drug is taken orally, regardless of food intake.

For adults For treatment of influenza and ARVI prescribed in the first 2 days - 2 tablets. 3 times a day, in the next 2 days - 1 tablet. 3 times/day. A total of 18 tablets per course lasting 4 days.

Prevention of influenza and ARVI carried out in 7-day cycles: 2 days - 2 tablets. 1 time/day, break for 5 days. Then the cycle is repeated. The duration of the preventive course is from 1 week to several months.

For treatment 2 tablets are prescribed. 3 times/day for 5 days. In total, for a course lasting 5 days - 30 tablets.

Children aged 3 to 6 years For treatment of influenza and ARVI prescribed in the first 2 days - 1 tablet. 2 times a day, in the next 2 days - 1 tablet. 1 time/day A total of 6 tablets per course lasting 4 days.

Children aged 6 years and older For treatment of influenza and ARVI prescribed in the first 2 days - 1 tablet. 3 times a day, in the next 2 days - 1 tablet. 2 times/day. A total of 10 tablets per course lasting 4 days.

U children aged 3 years and older prevention of influenza and ARVI carried out in 7-day cycles: 2 days - 1 tablet. 1 time/day, break for 5 days, then repeat the cycle. The duration of the preventive course is from 1 week to several months.

Side effects

Maybe: allergic reactions.

If any of these side effects worsen, or the patient notices any other side effects, he should inform the doctor.

Overdose

Treatment: In case of accidental overdose, it is recommended to prescribe plenty of fluids and induce vomiting.

Content

During seasonal acute illnesses, many are saved by antiviral drugs. It is difficult to figure out when to take such medications and when not to. The use of such drugs is often prescribed to people with weakened immune systems or for prevention if there is a seasonal epidemic of the virus.

Kagocel - instructions for use

Among modern drugs, one can highlight an effective inducer of interferon synthesis - Kagocel. The drug is positioned as an antiviral agent, capable of inducing the production of human interferon and helping to cope with intoxication of body cells during illness. Like other pills, it is not advisable to take the product without a doctor’s prescription. Before taking the tablets, you need to familiarize yourself with the characteristics of the drug Kagocel - instructions for use are available online.

Kagocel - instructions for use for children

If a child has acute signs of acute respiratory viral infection, or the child very often suffers from this disease throughout the year, it is possible to use this antiviral drug, because taking Kagocel tablets for children is allowed from 6 years of age. The dosage for a child is different, because... The child's body requires a lower concentration of the active substance. The course is only 4 days, from the third the child will already feel better. You need to know how to drink Kagocel for children:

• for prevention, take 1 tablet for two days with a break of five days, then repeat for 2 days, one tablet each;
• in the first two days from the moment symptoms are detected, you need to take one tablet three times a day, preferably after meals, and the next two days of treatment - one tablet in the morning and in the evening.

Kagocel - instructions for use for adults

Kagocel's abstract provides almost complete information on the drug, therefore, for each case of administration, a course of treatment is prescribed, however, before taking Kagocel for adults, you need to consult with a therapist. The tablets are most effective against the proliferation of viruses if used no later than the fourth day after the onset of symptoms. Detailed instructions for using Kagocel in tablets contain information on how to take the medicine for adults:

• the first two days of symptoms – 2 tablets three times a day;
• for the next two days, three times a day, one tablet.

Kagocel during pregnancy

Due to the fact that there is no clinical data for this medication regarding its use during pregnancy, the instructions indicate that it is not recommended to take Kagocel during pregnancy. The doctor will not prescribe such medicine to the mother during breastfeeding if she is sick with the flu. The age at which the active substances are safely tolerated by the body is at least 6 years.

Kagocel - composition

The manufacturer of the drug (Nearmedic Plus) reports that there are no analogues to its composition on the domestic market, and it has an affordable price. The composition of Kagocel is a sodium salt of complex polymers, which, when entering the body, cause the production of the so-called. late interferons, which stimulate the antiviral activity of all cells that are involved in the body's response. In the blood serum, the active substance reaches its maximum concentration after 48 hours, so after this period of time a noticeable effect occurs.

Kagocel - indications for use

The instructions contain almost comprehensive information about the action of the medicine, but the dose and course of treatment should be prescribed by a doctor taking into account the individual condition of the patient and the nature of the disease. If your doctor has prescribed Kagocel for you, the indications for its use may be different:

• prevention of influenza, ARVI;
• treatment of acute viral infections;
• treatment and prevention of herpes virus.

This medicine can be easily combined with other drugs from the antiviral category according to the instructions, as well as with antibiotics, so it can be prescribed if a viral infection is associated with a bacterial one. The symptoms of such diseases can be difficult to differentiate, therefore, after treatment of the infection, a complication in the form of sore throat may arise, for which antiviral drugs are no longer prescribed.

Kagocel - contraindications

The first and most important contraindications that the manufacturer warns about are breastfeeding, pregnancy, and young children under 6 years of age. The active substance easily penetrates through the placenta and into breast milk. If the risk from a viral infection is significantly higher than from the action of the drug, then it may be prescribed for the treatment of acute manifestations of the disease. The instructions warn that only a doctor can bypass contraindications after analyzing the situation in a specific case of the disease.

Kagocel - side effects

The package insert describes in detail possible side effects. Kagocel can cause individual intolerance and, rarely, allergies. But with the correct dosage, the drug practically does not cause a bad reaction. It is important to know that you cannot combine such medications with alcohol. The instructions emphasize that if any symptoms of intolerance occur, you must consult a doctor.

Price for Kagocel

The standard packaging of the drug contains a blister with 10 tablets, which provide a standard course of treatment. Where is it cheaper to buy and how much does Kagocel cost? It is available in most pharmacies in major cities. You can order a medicine using online stores to find its best price, where you can also read reviews about the medicine. The average price for tablets in Moscow pharmacies is 230 rubles, the cost can vary between 228-237 rubles. per package.